Clinical trials: Histological Response
Metastatic Solid Tumor, Colon Cancer
Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With CRC, NSCLC, and STS
The goal of this clinical trial is to determine the safety and efficacy of IP-001 for intratumoral injection administration following thermal ablation of a solid tumor.
- Conditions
- Metastatic Solid Tumor, Colon Cancer, Nonsmall Cell Lung Cancer, Soft Tissue Sarcoma
- Trial name
- INJECTABL-1 (NCT05688280)
- Testing
- 1.0% IP-001 for Injection
- Where
- 16 sites in United States, France and 3 more
- Volunteers
- 42 people
- Sponsor
- Immunophotonics, Inc.
Multiple Myeloma
A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation
The purpose of this study is to compare the efficacy, safety, and tolerability of ide-cel with lenalidomide (LEN) maintenance to that of LEN maintenance alone in adult participants with Newly Diagnosed Multiple Myeloma (NDMM) who…
- Trial name
- KarMMa-9 (NCT06045806)
- Testing
- idecabtagene vicleucel, Lenalidomide, Fludarabine
- Where
- 101 sites in United States, Australia and 16 more
- Volunteers
- 79 people
- Sponsor
- Celgene
Multiple Myeloma
A Study to Assess Renal Function Response to Treatment in Patients With Relapsed Multiple Myeloma and Creatinine Clearance
A prospective, multicentre, post-authorisation observational study. The objective of this study is assess the response of renal function in clinical practice to anti-multiple myeloma therapy in patients with relapsed MM and CrCl…
- Trial name
- MIR50 (NCT02849444)
- Testing
- Anti-myeloma treatment at physician discretion
- Where
- 40 sites in Spain
- Volunteers
- 326 people
- Sponsor
- Celgene
Pleural Mesothelioma, Pleural Diseases
The Diagnostic Accuracy and Clinical Value of FAPI PET in Pleural Mesothelioma
Seventy (N=70) patients with suspected pleural mesothelioma (PM) lesions referred to pleural biopsy will be recruited, and undergo an additional FAPI PET/CT at primary staging.
- Conditions
- Pleural Mesothelioma, Pleural Diseases, Cancer, FAPI
- Trial name
- FAPI-PM (NCT06790082)
- Testing
- [68Ga]Ga-FAPI-46 PET/CT
- Where
- Denmark
- Volunteers
- 70 people
- Sponsor
- Aalborg University Hospital
Adenocarcinoma, Adenocystic Carcinoma
The Registry of Oncology Outcomes Associated With Testing and Treatment
This study is to collect and validate regulatory-grade real-world data (RWD) in oncology using the novel, Master Observational Trial construct. This data can be then used in real-world evidence (RWE) generation.
- Conditions
- Adenocarcinoma, Adenocystic Carcinoma, Anal Cancer, Appendix Cancer
- Trial name
- ROOT (NCT04028479)
- Testing
- Biomarker Testing (L), Systemic Treatment (T), Patient Reported Outcomes (P)
- Where
- 2 sites in United States
- Volunteers
- 167 people
- Sponsor
- Taproot Health
Acute Myeloid Leukemia
Biomarkers for Personalized Early Assessment of Response During Salvage Chemotherapy in People With Relapsed or Refractory Acute Myeloid Leukemia (PEARL15)
Background: -Acute myeloid leukemia (AML) is a cancer of the white blood cells. It can be fatal. Standard treatment involves intensive chemotherapy. Not all treatment works.
- Trial name
- NCT02527447
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Ewing Sarcoma
Prospective Evaluation of Dynamic Serum ProGRP for Treatment Response Monitoring in Ewing Sarcoma
This single-center prospective observational study aims to evaluate whether longitudinal changes in serum pro-gastrin-releasing peptide (ProGRP) reflect treatment response in patients with newly diagnosed Ewing sarcoma.
- Trial name
- NCT07725783
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Peking University People's Hospital
Recurrent Melanoma, Stage IIB Melanoma (Locally Advanced)
Dabrafenib Alone and in Combination With Trametinib Before Surgery in Treating Patients With Locally or Regionally Advanced Melanoma That Can Be Removed By Surgery
This phase II trial studies how well giving dabrafenib alone and in combination with trametinib before surgery works in treating patients with advanced melanoma that can be removed by surgery.
- Conditions
- Recurrent Melanoma, Stage IIB Melanoma (Locally Advanced), Stage IIC Melanoma (Locally Advanced), Stage IIIA Melanoma
- Trial name
- NCT01701037
- Testing
- dabrafenib, trametinib, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Advanced Adult Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8
An Investigational Scan (Magnetic Resonance Elastography) in Detecting Treatment Response in Patients With Advanced Liver Cancer
This trial studies how well an investigational scan (magnetic resonance elastography [MRE]) works with standard imaging (magnetic resonance imaging [MRI]) in detecting response to treatment in patients with liver cancer that has…
- Conditions
- Advanced Adult Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC v8, Stage IIIB Hepatocellular Carcinoma AJCC v8
- Trial name
- NCT04022746
- Testing
- Magnetic Resonance Elastography, Magnetic Resonance Imaging
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- M.D. Anderson Cancer Center
Non-Small Cell Lung Cancer
Biomarkers of Response to Pembrolizumab Combined With Chemotherapy in Non-Small Cell Lung Cancer (KEYNOTE-782, MK-3475-782)
Participants with Stage IV nonsquamous non-small cell lung cancer (NSCLC) without prior systemic treatment will be treated with standard of care pembrolizumab combined with platinum-doublet chemotherapy for 4 cycles, then…
- Trial name
- KEYNOTE-782 (NCT03664024)
- Testing
- Pembrolizumab, Pemetrexed, Carboplatin
- Where
- 15 sites in United States, Canada and 3 more
- Volunteers
- 118 people
- Sponsor
- Merck Sharp & Dohme LLC
Leukemia
Chemotherapy Plus Monoclonal Antibody in Treating Patients With Acute Promyelocytic Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to…
- Trial name
- NCT00016159
- Testing
- filgrastim, lintuzumab, arsenic trioxide
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Esophageal Cancer, Esophageal Adenocarcinoma
Metabolomic and BH3 Profiling of Esophageal Cancers: Identification of Novel Assessment Methods of Treatment Response for Precision Therapy
Background: The number of patients with esophageal cancer keeps rising. For many patients, a combination of surgery, chemotherapy, and radiation is necessary to completely treat the disease.
- Conditions
- Esophageal Cancer, Esophageal Adenocarcinoma, Esophageal Squamous Cell Cancer, Esophageal Neoplasms
- Trial name
- NCT03223662
- Testing
- Chemoradiotherapy, Esophagectomy
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- National Cancer Institute (NCI)
Adenocarcinoma Esophagus
Circulating Tumor DNA (ctDNA) in Locally Advanced Esophageal and Gastroesophageal (GE) Junction Adenocarcinoma
This is an observational study to determine the feasibility of assessing tumor response utilizing ctDNA in patients of locally advanced esophageal and gastroesophageal junction (LA-EA/GEJ) cancer undergoing total neoadjuvant…
- Trial name
- TRACT DNA (NCT05067842)
- Testing
- Circulating tumor DNA(ctDNA) level measurement
- Where
- United States
- Sponsor
- Medical College of Wisconsin
Steroid-Refractory Acute Graft Versus Host Disease
A Study to Compare T-Guard vs Ruxolitinib for Treatment of Steroid-Refractory Acute Graft-vs-Host Disease (BMT CTN 2002)
This is an open-label, randomized, Phase 3, multicenter trial, which has been designed to compare the efficacy and safety of T-Guard to ruxolitinib in patients with Grade III or IV Steroid-Refractory acute Graft-Versus-Host…
- Trial name
- 2002 (NCT04934670)
- Testing
- T-Guard, Ruxolitinib
- Where
- 48 sites in United States, Belgium and 7 more
- Volunteers
- 12 people
- Sponsor
- Xenikos
Uterine Myoma, Adenomyosis
Use of Dexamethasone in Uterine Artery Embolization
The primary purpose of this study is to investigate the effects of dexamethasone on inflammatory reactions after uterine artery embolization.
- Trial name
- NCT02056717
- Testing
- Dexamethasone, Normal saline
- Where
- South Korea
- Volunteers
- 64 people
- Sponsor
- Severance Hospital
Multiple Myeloma
Non-interventional Study on Time to Response and Quality of Life in Relapsed/Refractory Multiple Myeloma When Treated With Lenalidomide in Second Line
The purpose of this study is to quantify the burden of treatment in relapsed or refractory multiple myeloma in patients receiving lenalidomide after one prior treatment for myeloma.
- Trial name
- NCT01430546
- Where
- Sweden
- Volunteers
- 133 people
- Sponsor
- Hareth Nahi
Melanoma
18F-FLT PET Imaging in Patients With Advanced Melanoma
In the current study, advanced positron emission tomography/computed tomography (PET/CT) and positron emission tomography/magnetic resonance (PET/MR) imaging methods will be used to validate our hypothesis that melanoma patients…
- Trial name
- NCT02891616
- Testing
- fludeoxyglucose F 18, Positron emission tomography-computed tomography, 18F-fluorothymidine
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Washington University School of Medicine
High Grade Gliomas, Hypoxia Brain
Brain Radiotherapy Imaging for High-grade Glioma Using Hypoxia Targeting Through Oxygen-Enhanced Response
High-grade gliomas (HGGs) are the most common type of brain cancer in adults. Life expectancy for patients with HGGs is low. Radiotherapy aims to cure the tumour, but this is hard because HGGs are resistant to treatment.
- Conditions
- High Grade Gliomas, Hypoxia Brain, Glioblastoma (GBM), Brain Neoplasms, Adult
- Trial name
- BRIGHTER (NCT07670455)
- Testing
- Oxygen-Enhanced MRI (OE-MRI)
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- The Leeds Teaching Hospitals NHS Trust
Carcinoma, Squamous Cell
A Study to Evaluate Immune Biomarker Modulation in Response to VTX-2337 in Combination With an Anti- PD-1 Inhibitor in Head and Neck Cancer
This is an open label, Phase 1b pre-operative window of opportunity biomarker trial to analyze the combination of intravenous (IV) anti-PD-1 inhibitor, nivolumab, given along with toll-like receptor 8 (TLR 8) agonist motolimod…
- Trial name
- NCT03906526
- Testing
- VTX-2337, Nivolumab
- Where
- 12 sites in United States
- Volunteers
- 15 people
- Sponsor
- Celgene
Renal Cell Carcinoma
Quantitative Imaging Metrics From CECT in Measuring Disease Response or Progression in Patients With Kidney Cancer
This pilot research trial studies quantitative imaging metrics derived from contrast enhanced computed tomography (CECT) in enhancing assessment of disease status in patients with kidney cancer.
- Trial name
- NCT02370290
- Testing
- Medical Chart Review, Informational Intervention
- Where
- United States
- Volunteers
- 74 people
- Sponsor
- University of Southern California
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.